Citius Oncology, Inc. (CTOR:NASDAQ) closed at $0.768 on October 16, 2026, up 2.94% on the day. The stock trades 60.6% below its 52-week high of $1.95 and 56.4% above its 52-week low of $0.491. Over the past year, it lost 54.8%. Citius Oncology, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -5.50% | -24.72% | +34.72% | -16.89% | -54.83% |
In 252 trading sessions since October 16, 2025, CTOR closed higher on 106 days (42%). Its best day was March 31, 2026 (+25.76%) and its worst was December 2, 2025 (-20.73%). The stock moved 10% or more in a single session 19 times. It opened at least 5% above the previous day's high 2 times.
Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds 400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology s competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals.
Find more stocks like CTOR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.